RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada - RELEVANCE
Study identifier:D4191R00028
ClinicalTrials.gov identifier:NCT05933044
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Retrospective Observational, Multi-Centre, Cohort Study to Understand Real-World Treatment Patterns and Clinical Outcomes of Adult Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada
Medical condition
Non-small Cell Lung Cancer
Phase
N/A
Healthy volunteers
No
Study drug
Durvalumab
Sex
All
Actual Enrollment
662
Study type
Observational
Age
18 Years - 130 Years
Date
Study Start Date: 19 Nov 2021
Primary Completion Date: 31 Aug 2022
Study Completion Date: 31 Aug 2022
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Aug 2023 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Durvalumab cohort All stage III non-small cell lung cancer (NSCLC) patients who received durvalumab | Drug: Durvalumab Chemoradiotherapy plus durvalumab Other Name: Imfinzi |
| Non-durvalumab cohort All stage III non-small cell lung cancer (NSCLC) patients who did not receive durvalumab | - |
